-
1.发明授权Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators 失效异噻唑-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂公开(公告)号：US07960380B2
公开(公告)日：2011-06-14
申请号：US12725669
申请日：2010-03-17
申请人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
发明人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
IPC分类号： A61K31/5355 , A61K31/501 , A61K31/4523 , A61K31/4427 , A61K31/427 , A61K31/4255 , C07D275/02 , C07D233/54 , C07D413/02 , C07D401/02 , C07D239/02 , C07D211/00 , C07D417/02
CPC分类号： C07D275/03 , C07D417/12 , C07D417/14
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新型化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或bgr; （NR1H2）和治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
2.发明申请Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators 失效异噻唑啉-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂公开(公告)号：US20100227847A1
公开(公告)日：2010-09-09
申请号：US12725669
申请日：2010-03-17
申请人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
发明人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
IPC分类号： A61K31/427 , A61P3/10 , A61P3/06 , A61P9/10 , A61P25/28 , A61K31/425 , A61K31/4439 , A61K31/4545 , A61K31/454 , A61K31/5377
CPC分类号： C07D275/03 , C07D417/12 , C07D417/14
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新型化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或bgr; （NR1H2）和治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
3.发明授权Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators 失效异噻唑-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂公开(公告)号：US07723333B2
公开(公告)日：2010-05-25
申请号：US11813470
申请日：2006-01-09
申请人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
发明人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
IPC分类号： A61K31/5355 , A61K31/501 , A61K31/4523 , A61K31/4427 , A61K31/427 , A61K31/4155 , C07D275/02 , C07D233/54 , C07D413/02 , C07D401/02 , C07D239/02 , C07D211/00 , C07D417/02
CPC分类号： C07D275/03 , C07D417/12 , C07D417/14
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新型化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或bgr; （NR1H2）和治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
4.发明申请Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators 失效异噻唑啉-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂公开(公告)号：US20090005353A1
公开(公告)日：2009-01-01
申请号：US11813470
申请日：2006-01-09
申请人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
发明人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
IPC分类号： A61K31/397 , C07D275/02 , A61K31/425 , C07D417/02 , A61K31/4439 , C07D211/06 , A61K31/4545 , A61K31/501 , A61P29/00 , A61P25/00 , A61P9/00 , C07D403/14 , A61K31/454 , C07D401/14 , A61K31/506 , C07D295/00 , A61K31/5377
CPC分类号： C07D275/03 , C07D417/12 , C07D417/14
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
5.发明授权Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators 失效异噻唑-3（2H） - 酮1,1-二氧化物的衍生物作为肝X受体调节剂公开(公告)号：US07582629B2
公开(公告)日：2009-09-01
申请号：US11813481
申请日：2006-01-09
申请人： Jonas Boström , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
发明人： Jonas Boström , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
IPC分类号： A61K31/535 , A61K31/445 , A61K31/425 , C07D415/00 , C07D413/00 , C07D417/00 , C07D275/02
CPC分类号： C07D275/03 , C07D417/12
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
6.发明申请DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR 审中-公开异硫氰酸-3（2H） - 酮-1,1-二氧化物作为肝脏X受体调节剂的衍生物公开(公告)号：US20100016321A1
公开(公告)日：2010-01-21
申请号：US12507924
申请日：2009-07-23
申请人： Jonas Bostrom , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
发明人： Jonas Bostrom , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
IPC分类号： A61K31/5377 , A61P3/00 , A61P25/00
CPC分类号： C07D275/03 , C07D417/12
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新化合物，用于制备这些化合物的方法，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和治疗 和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
7.发明申请Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators 失效异噻唑-3（2H） - 一种1,1-二氧化物作为肝X受体调节剂的衍生物公开(公告)号：US20080255122A1
公开(公告)日：2008-10-16
申请号：US11813481
申请日：2006-01-09
申请人： Jonas Bostrom , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
发明人： Jonas Bostrom , Kay Brickmann , Anders Broo , Robert Judkins , Lanna Li , Pernilla Sandberg , Marianne Swanson , Christer Westerlund , Patrik Holm
IPC分类号： A61K31/5355 , C07D275/03 , A61K31/425 , A61P25/00 , C07D401/02 , A61K31/497 , A61K31/4725 , C07D413/14 , A61K31/454 , C07D417/02
CPC分类号： C07D275/03 , C07D417/12
摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
公开(公告)号：US07432288B2
公开(公告)日：2008-10-07
申请号：US10564235
申请日：2004-07-08
申请人： Jonas Boström , Kay Brickmann , Patrik Holm , Pernilla Sandberg , Marianne Swanson , Christer Westerlund
发明人： Jonas Boström , Kay Brickmann , Patrik Holm , Pernilla Sandberg , Marianne Swanson , Christer Westerlund
IPC分类号： A61K31/4439 , C07D401/04
CPC分类号： C07D405/06 , C07D207/456 , C07D401/06 , C07D405/12 , C07D405/14 , C07D413/06
摘要： The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR)α(NR1H3) and/or β(NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及一些式I化合物的制备方法，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）以及在治疗和 /或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
公开(公告)号：US20060199857A1
公开(公告)日：2006-09-07
申请号：US10561126
申请日：2004-06-16
IPC分类号： A61K31/381 , A61K31/277 , A61K31/192 , C07C317/30 , A61K31/195
CPC分类号： C07C323/56 , C07C317/46 , C07C323/60 , C07D333/18
摘要： Substituted 3-phenylpropionic acid derivatives, processes for preparing such compounds, their utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.
摘要翻译： 取代的3-苯基丙酸衍生物，制备这些化合物的方法，它们在治疗临床病症中的应用，包括脂质紊乱（血脂异常），不论是否与胰岛素抵抗有关，其治疗用途的方法和含有它们的药物组合物。
-
10.发明申请5-Thioxo-1,5-Dihydro-2H-Pyrrol-2-One Derivatives As Liver X Receptor Modulators 审中-公开5-硫代-1,5-二氢-2H-吡咯-2-酮衍生物作为肝X受体调节剂公开(公告)号：US20080255207A1
公开(公告)日：2008-10-16
申请号：US11813467
申请日：2006-01-09
申请人： Patrik Holm , Lanna Li
发明人： Patrik Holm , Lanna Li
IPC分类号： A61K31/4439 , C07D401/12
CPC分类号： C07D207/44 , C07D401/06 , C07D403/12 , C07D405/12
摘要： The present invention relates to certain novel compounds of the Formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α(NR1H3) and/or β(NR1H2) and in treating clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 本发明涉及式（I）的某些新型化合物，用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.063 秒)
